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Abstract
Purpose Fatigue is a symptom with a relevant impact on
the daily lives of cancer patients and is gaining importance
as an outcome measure. The Perform Questionnaire (PQ) is
a new scale originally developed among Spanish-speaking
patients for the assessment of perception and beliefs about
fatigue in cancer patients.
Methods An observational longitudinal multicenter study
was carried out on cancer patients with fatigue. Fatigue-
specific measures (FACT-F), generic health-related quality-
of-life measures (NHP), and PQ were gathered at baseline
and 3 months later. Feasibility, reliability (internal consis-
tency and test–retest), validity, sensitivity to change, and
minimally important differences were analysed.
Results Four hundred thirty-seven patients were included in
the study: 60.5% were women, the mean age was 59.1 years,
the mean time from diagnosis was 2.2 years, 33.6% of
patients had breast cancer, and 29.1% had anaemia
(haemoglobin (Hb) <11 g/dL). Low levels of missing items
and ceiling/floor effects (<10%) were found. The overall
Cronbach’salphaandintraclasscorrelationcoefficientwere
0.94 and 0.83, respectively. The PQ score was associated
with fatigue intensity, the need for a caregiver, and the Hb
level. Its association was stronger with the FACT-F than
with non-specific health measures (NHP). The PQ showed
good sensitivity to change for improved and worsening
health status. A minimally important difference of 3.5 was
estimated in patients whose Hb level had improved by at
least 1 g/dL.
Conclusions The PQ measured the attitudes and beliefs
about fatigue among cancer patients in clinical practice and
showed good psychometric properties among Spanish-
speaking patients.
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According to studies published recently within the cancer
epidemiology and health research outcomes areas, fatigue is
one of the most frequent symptoms with a major impact on
oncology patients [1–3]. Cancer-related fatigue (CRF),
which has been defined as a “distressing persistent sub-
jective sense of physical, emotional, and/or cognitive
tiredness” [4], is a very prevalent symptom that can affect
more than three quarters of oncology patients [5–8]. Fatigue
is undertreated [5, 6], prevents a “normal” life [9], and
could have a greater impact on the quality of life than pain
or depression, which are symptoms also observed frequent-
ly in cancer patients [5]. Excellent reviews addressing
fatigue in cancer patients and its associated problems have
been published recently [10–12].
The need to deepen our understanding of the impact of
fatigue interventions on outcomes such as quality of life
[13, 14] has been recognised recently, for which adequate
and duly validated and developed instruments are required.
This underscores yet again the importance of integrating
clinical and outcomes research in daily clinical practice
[15]. A new instrument to measure patient perceptions of
fatigue in cancer and its treatment has been developed: the
Perform Questionnaire [16], originally developed for
Spanish-speaking patients and created with the intention
of being a feasible and valid tool for evaluating, from a
patient perspective, the perceptions associated with fatigue
within usual clinical practice. Initially, the instrument
development procedure focused on item generation and
item reduction, as well as on exploring the structural
validity and internal consistency of the instrument [16],
while assuring certain formal characteristics in terms of
length, scoring system, etc., which are characteristics that
can often jeopardise the feasibility of the tool in usual
clinical practice, as demonstrated in other health areas [17].
Subsequently, the psychometric properties of the new
tool were assessed, an indispensable requirement for
fulfilling the purpose of using the new tool in the target
population. The aim of this paper was to report the findings
of the validation study of the Perform Questionnaire.
Patients and methods
To assess the reliability of the new PQ, as well as its
validity and sensitivity to change, we performed a prospec-
tive and observational study between November 2005 and
September 2006 in the oncology and palliative care
departments of 50 Spanish public hospitals. Each centre
consecutively included patients with the following charac-
teristics: (a) ambulatory and over 18 years of age; (b) with a
diagnosis of cancer (any site and period of disease duration,
as long as they were capable of completing the study
questionnaires); (c) with a self-rated fatigue intensity
≥30 mm on a 100-mm visual analogue scale (VAS) at the
time of the study visit [4]; and (d) with a life expectancy of
over 6 months. All patients provided informed consent to
participate in the study, and the study was approved by the
Ethics Committee of the Hospital Clínic i Provincial in
Barcelona and have therefore been performed in accordance
with the ethical standards laid down in the 1964 Declara-
tion of Helsinki.
Patient assessments were performed at the time of
inclusion in the study and 3 months later to assess test–
retest reliability and sensitivity to change. We collected data
regarding sociodemographic factors (i.e. sex, age, level of
education, and level of family care required) and clinical
characteristics (including cancer location, extent of the
disease, haemoglobin level, cancer treatment, time since
diagnosis, Karnofsky index on inclusion, and intensity of
fatigue measured on a 100 mm horizontal VAS).
The PQ [16] is a new questionnaire developed by
clinicians that uses patient perspectives for assessing the
perception of fatigue in cancer. It consists of 12 items with
responses on a five-point ordinal scale. The 12 items are
distributed in three dimensions: “Physical Limitations”,
“Activities of Daily Living”, and “Beliefs and Attitudes”.
An overall score and three-dimension scores are obtained,
with low scores indicating worse patient perception of
fatigue.
The new questionnaire was self-administered together
with the Functional Assessment of Cancer Therapy—
Fatigue (FACT-F) [18, 19]. The FACT-F consists of 13
items related to fatigue with responses to the individual
items on a five-point ordinal scale and overall scores range
from 13 (no impairment) to 65 (greatest impairment). The
new questionnaire was also self-administered together with
the short version of the Nottingham Health Profile (NHP)
[20, 21]. The NHP-22 questionnaire is a generic health-
related quality-of-life measure that has two summary
scores: physical and psychological dimensions [21]. Each
dimension score ranges from 0 (minimum impact in Health-
Related Quality of Life (HRQOL)) to 100 (maximum
impact in HRQOL).
Patients were also asked to rate the new questionnaire’s
ease of use on a scale ranging from “Very difficult to
complete” to “Very easy to complete”, and the time taken to
complete the questionnaire was recorded.
A “health status transition” item was self-administered at
the second visit, to assess changes in health status
perception from the first visit. Patients provided answers
based on a Likert-type ordinal scale with 13 response
options ranging from “have greatly improved” to “have
greatly worsened”. The results were used in the analysis of
sensitivity to change.
658 Support Care Cancer (2011) 19:657–666Statistical analyses
The questionnaire’s feasibility was assessed by examining
responses to the ease of use question and the time taken to
complete the questionnaire. The lost information was also
assessed by calculating the completion rate (the percentage
of responders with no missing data in any of the 12 items)
and the range of missing answers (the maximum number of
missing responses per item).
The distribution of the overall and dimension scores was
analysed by calculating mean scores, standard deviations
(SDs), observed score ranges, and floor and ceiling effects
(the proportion of patients with the worst and the best
possible scores, respectively) for the overall score and for
each dimension of the PQ.
The instrument’s internal consistency was assessed by
estimating Cronbach’s alpha (CA) [22] coefficients for
individual dimensions and the overall score at the baseline.
We hoped to obtain a CA over 0.70, as recommended in the
literature [23, 24]. The 3-month test–retest reliability was
assessed by calculating the intraclass correlation coefficient
(ICC) between visits among patients who did not report any
significant change (<5 mm) in VAS fatigue intensity be-
tween study visits.
The known groups’ validity was tested by determining
whether the instrument was able to discriminate between
patient groups likely to differ in fatigue perception accord-
ing to variables such as intensity of fatigue, anaemia
prevalence, level of Hb, and need for a caregiver.
The convergent validity was tested by estimating
Pearson’s correlation coefficients between the PQ and
scores of the FACT-F, the NHP, and the Karnofsky index
[25]. We expected correlations to be higher between the
PQ and the FACT-F, as both are disease-specific
instruments, than between the PQ and other health
measures such as the NHP and the Karnofsky index.
The sensitivity to change was assessed by calculating
the effect size (ES; i.e. the standardised mean score
change) and standardised response mean (SRM) in the
subgroup of patients who reported at least a “small
improvement” on the health status transition item as
well as in the subgroup of patients who reported at
least a “small deterioration” on the aforementioned
item. ES values of approximately 0.2 were considered
as representing a small change, while values of
approximately 0.5 indicated a moderate change, and
values of approximately 0.8 or higher represented a
large change in the attribute of interest [26]. The SRM
was calculated by dividing the mean change in score by
the SD of the change scores between the two study
visits [24].
To improve the interpretation of the observed numerical
differences in the PQ, the minimally important difference
(MID) that would imply a clinically meaningful outcome
was determined according to the method described in
previous studies [27]. An Hb increase of 1 g/dL was
considered the minimally important clinical change neces-
sary to evaluate fatigue results. “Improved” patients were de-
fined as those who experienced an increase in Hb ≥1g / d L .
“Stable” patients had a change in Hb<1 g/dL to a lower limit
of −1 g/dL. The difference in the mean PQ change score
between the improved and stable groups was considered the
MID of the measure.
Statistical analyses were carried out using the SAS
software [28].
Results
The study population consisted of 437 patients, whose
characteristics are shown in Table 1. The mean age of the
study population was 59.1 years (SD, 11.8), and 60.5% of
patients were female. The most prevalent type of cancer
was breast cancer (33.6%), followed by lung (14.9%) and
colon (11.4%) cancer. Time from diagnosis was 2.2 years,
with a current Karnofsky mean score of 81.3 (SD, 11.6).
Fifty-four and seven percent of patients had metastasis, and
almost a third of the patients presented with anaemia at
inclusion. Only 10% of the sample was enrolled in follow-
up, while the remaining 90% was undergoing cancer
treatment. The most prevalent treatment in the study
population was chemotherapy (as a single therapy or as
combined therapy), followed by radiotherapy, which was
used in only 14% of the sample.
As Table 2 shows, more than 80% of the patients
considered that the PQ was very easy or easy to answer,
and the mean time required for its administration was under
9 min. Over 80% of the study patients answered 100% of
the questionnaire items. In general, all of the items showed
low levels of lost answers (<4%), with the exception of
question 8 (“I’ve felt bad about feeling tired at work”),
which was left unanswered by 16% of the patients. Floor/
ceiling effects were negligible (<2%) for the overall score
and low (<9%) for all dimensions. The highest floor/ceiling
effect (8.6%) was detected in the “Physical limitations”
dimension. The Cronbach’s alpha for the overall score was
0.94, and it was at least 0.80 for each dimension. The ICC
values found in the subgroup of patients considered
“stable” were above 0.75 for the dimensions and 0.83 for
the overall score.
Patients with the highest (severe) levels of fatigue
intensity obtained worse Perform overall and dimension
scores than patients with moderate fatigue intensity (P<
0.0001; Table 3). Patients who needed a caregiver, anaemic
patients, and patients with lower levels of Hb obtained
worse Perform overall (P=0.0001 to 0.0006) and dimen-
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not need a caregiver, were non-anaemic, and had higher
levels of Hb. The Pearson’s correlation coefficient between
the Perform overall score and the Hb level at baseline was
0.18 and ranged between 0.14 (“Physical limitations”) and
0.20 (“Activities of daily living”).
We used a linear regression model to assess the
multivariate association between the Perform overall
score and several clinical characteristics (Table 4).
Significant results were obtained using the model for
sociodemographic variables (educational level); however,
they were predominant for clinical characteristics, such
as the need for a caregiver, cancer location, fatigue
intensity level, Karnofsky score, the presence or absence
of cancer treatment, the presence or absence of palliative
treatment, and the time from diagnosis. These clinical
characteristics were independently associated with the
Perform overall score (P=0.0001 to 0.03) and explained
31% of the variance.
The comparison of PQ scores with the other health
measures (i.e. FACT-F, NHP, and Karnofsky index)
revealed stronger correlations between Perform scores and
the FACT-F (overall=0.80; dimensions=0.68–0.75) than
between Perform scores and the NHP dimensions (overall
Perform with Physical NHP=0.68; overall Perform with
Psychological NHP=0.56; Perform dimensions with Phys-
ical NHP=0.57–0.67; Perform dimensions with Psycholog-
ical NHP=0.44–0.55) or between Perform scores and
Karnofsky index (overall=0.35; dimensions=0.23–0.26;
Fig. 1).
The sensitivity to change (Table 5) was assessed
among the subgroup of 208 patients who self-reported
an improvement in their health status since the time of
their first visit 3 months earlier, as well as among the
subgroup of 84 patients who self-reported deterioration
in their health status since their first visit. In general,
the ES and the SRM values were higher for patients
w h ow o r s e n e dt h a nf o rp a t i e n t sw h oi m p r o v e d .F o r
instance, the ES for the Perform overall score among
patients who improved indicated a moderate health
improvement (0.57). However, the ES for the Perform
overall score among patients who worsened suggested
great health deterioration (−1). Perform dimension
scores also behaved according to this pattern (ES for
improved patients=0.5–0.6; ES for worsened patients=
0.73–0.83; Fig. 2).
Eighty-seven patients experienced an increase in Hb ≥1
g/dL, while 201 patients remained “stable” at 3 months
(Table 5). The mean change in Perform overall score for
“Hb-stable” patients was 0.03, and the mean Perform
overall score change for “Hb-improved” patients was
3.72. The MID for the Perform overall score, which
implied a clinically meaningful outcome, was a score
Table 1 Baselinecharacteristicsofthevalidationstudysample(N=437)
Variables Data
Sex, N (%)
Women 264 (60.5)
Age, mean years (SD) 59.1 (11.8)
Educational level, N (%)
No formal education 92 (22)
Primary education 181 (43.8)
Secondary education 81 (19.4)
University or similar 62 (14.8)
Carer status, N (%)
Patient does not need care from other person 292 (68.5)
Patient needs and receives care from the
family, the caregiver, or both
134 (31.5)
Time from diagnosis, mean years (SD) 2.21 (3.9)
Karnofsky score on inclusion,
mean (SD) [min, max]
81.3 (11.6) [50, 100]
Cancer location, N (%)
Breast 147 (33.6)
Lung 65 (14.9)
Colon 50 (11.4)
Rectum 34 (7.8)
Ovary 27 (6.2)
Prostate 22 (5)
Other
a 96 (22)
Cancer extension, N (%)
Local 90 (20.8)
Loco regional 106 (24.5)
Metastasis 237 (54.7)
Hb <11 g/dL, N (%) 127 (29.1)
Hb (g/dL), mean (SD) [min, max] 12 (1.7) [6.9, 18]
Treatment status, N (%)
Follow-up surveillance 43 (9.8)
Active treatment 394 (90.2)
Type of cancer treatment
b, N (%)
Chemotherapy 368 (84.2)
Radiotherapy 60 (13.7)
Hormone therapy 48 (11)
Monoclonal antibodies 41 (9.4)
Interferon 6 (1.4)
VAS fatigue score on inclusion, mm;
mean (SD) [min, max]
c
54.3 (15.1) [30, 95]
VAS fatigue level on inclusion, N (%)
Moderate (30–60 mm) 227 (65.6)
Severe (>60 mm) 119 (34.4)
Following a fatigue treatment, N (%) 152 (34.8)
FACT-F
d, mean (SD) 35.9 (10.5)
NHP-22
e, mean (SD)
Physical summary score 33.4 (24.1)
Psychological summary score 34.2 (26.8)
SD standard deviation, min minimum, max maximum, Hb haemoglo-
bin, VAS visual analogue scale, NHP Nottingham Health Profile,
FACT-F Functional Assessment of Cancer Therapy—Fatigue
aIncludes bladder (N=18), pancreas (N=16), lymphoma (N=12), head and
neck (N=11), stomach (N=10), and several other cancers with N<5
bIncludes indiscriminately indications in single therapy and combined
therapy
cFatigue was measured on a 100-mm, horizontal VAS
dGlobal score ranges from 13 (no impairment) to 65 (greatest impairment)
eDimension scores range from 0 (minimum impact in HRQOL) to 100
(maximum impact in HRQOL)
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3.72).
Discussion
The PQ, like any questionnaire or health scale meant for
use in clinical research or clinical practice, must be
guaranteed by rigorous validation and development
procedures, as described in the literature [23, 24, 29].
In this sense, the PQ was developed, modified, and
validated using standardised test construction methods
consistent with US Food and Drug Administration guide-
lines [29].
The PQ is a tool originally developed using Spanish-
speaking patients from Spain; therefore, its application
to Spanish speakers within a Hispanic culture would
be relatively easy after correction for cultural adaptation
according to the agreed-upon guidelines for this
purpose [30]. Moreover, the PQ was created with the
intention of being a feasible, valid, and useful tool for
assessing, from a patient perspective, the perceptions
associated with fatigue in cancer within usual clinical
practice. That is to say, this measure was developed
with the belief that it could be converted into a real tool
to be used by physicians and health professionals who
normally manage and assist oncology patients. There-
fore, its development process has been lengthy and
meticulous, and the validation performed and reported
in this article tested exhaustively some of the most
relevant psychometric properties and characteristics for
the use of health measures in clinical practice [30].
The PQ was well received by the study population.
Its administration required less than 9 min, and >80%
of the subjects classified it as “very easy” or “easy” to
answer. Importantly, there was a low level of lost
answers for all items, with the exception of the item
“I’ve felt bad about feeling tired at work,” which was
associated with a rate of lost answers of 16%. Taking
into account that oncology patients are often not fit
enough to work and that the format of the administered
questionnaire did not include item responses like “not
applicable” or “does not apply”, the aforementioned
16% probably included cases that understood the item
Table 2 Feasibility, score distributions, and reliability of the Perform Questionnaire (N=437)
Physical limitations Activities of
daily living
Beliefs and attitudes Global score
a
Items (N)3 3 3 1 2
Mean 11.5 11.7 11.3 34.8
SD 4.7 3.9 4.5 12
Time taken for administration, mean (SD) –– – 8.8 (8.9)
Easy or very easy to answer the questionnaire, N (%) –– – 343 (81.1)
Completion rate
b, N (%) 419 (95.88) 417 (95.42) 358 (81.92) 351 (80.32)
Range of missing answers, N (%) 2.5% (item 1)–
3.7% (item 2)
2.3% (item 6)–
16.9% (item 8)
2.3% (item 12)–
3.7% (item 9)
2.3% (items 6,12)–
16.9% (item 8)
Theoretical range
a 4–20 4–20 4–20 12–60
Observed range
a 4–20 4–20 4–20 12–60
Floor
c (%) 8.6 2.1 6.9 1.7
Ceiling
d (%) 4.3 0.9 1.6 0.3
Internal consistency, CA 0.90 0.80 0.85 0.94
Test–retest reliability among stable patients (N=64)
e
Mean score (SD) at visit 1 11.9 (4.6) 11.7 (3.8) 11.7 (4.4) 35.5 (12.1)
Mean score (SD) at visit 2 11.5 (4.3) 11.5 (3.5) 11.0 (44.4) 34.3 (11.5)
ICC 0.77 0.76 0.84 0.83
CA Cronbach’s alpha, ICC intraclass correlation coefficient, SD standard deviation
aLow scores indicate worse patient perception of CRF
bPercentage of respondents with no missing data in any of the 12 items
cPercentage of patients with the worst possible score
dPercentage of patients with the best possible score
eStability defined as a change <5 mm in the VAS fatigue between study visits
Support Care Cancer (2011) 19:657–666 661in question but were unable to answer, as none of the
five response options was adequate. In further studies
regarding the PQ, this point will have to be corrected,
and the option “not applicable” or “does not apply” will
be added. Nevertheless, the response rate for the
questionnaire (patients with all 12 items answered) was
over 80%. These results are especially satisfactory
within a sample of oncology patients whose common
and main characteristic are precisely those of suffering
from fatigue while responding to the measure.
Some patients obtained the worst or the best possible
overall scores and dimension scores, which suggests that
the questionnaire satisfactorily covers the perceptions of
fatigue as presented by the target population under study
[31]. The analysis of the internal consistency yielded
satisfactory results. The Cronbach’s alpha value obtained
for the questionnaire’s summary score (i.e. with all 12
items) was well over 0.70 (Table 2), which is usually
considered a standard value [24] and verges on what
some authors [23] consider a value that would permit the
administration and individual interpretation of the ques-
tionnaire without additional samples or patient popula-
tions. The Cronbach’s alpha values for the three
dimensions of the PQ were positive and comfortably
above standard values. The test–retest reliability, another
measure of reliability, was analysed using patients who did
not report any significant change (<5 mm) in the VAS
fatigue intensity between study visits. Regarding the
“stable” subgroup, the questionnaire showed a reproduc-
ibility of satisfactory scores (ICC >0.70) and was within
accepted standards [24]b o t hf o rs u m m a r ys c o r e sa n df o r
dimension scores [32–34].
Table 3 Mean (SD) scores for perform questionnaire overall and dimensions scores (low scores indicate worse patient perception of cancer-
related fatigue), according to clinical baseline characteristics (N=437)
Physical
limitations
Activities of
daily living
Beliefs and
attitudes
Global score
VAS fatigue level on inclusion, mean (SD)
Moderate (30–60 mm) 12.4 (4.6) 12.6 (3.6) 12.3 (4.3) 37.7 (11.3)
Severe (>60 mm) 9.3 (4.1) 9.5 (3.6) 8.9 (4) 28 (10.6)
P value <0.0001 <0.0001 <0.0001 <0.0001
Caregiver
Patient needs caregiver 9.6 (4.4) 10.5 (3.9) 9.2 (4.1) 29.6 (11.6)
Patient does not need caregiver 12.3 (4.6) 12.2 (3.8) 12.2 (4.3) 37 (11.7)
P value <0.0001 0.0001 <0.0001 <0.0001
Anaemia prevalence
Anaemic patients (Hb<11 g/dL) 10.5 (4.7) 10.6 (3.7) 10.1 (4.5) 31.5 (11.6)
Non-anaemic patients (Hb>11 g/dL) 12 (4.6) 12.2 (3.8) 11.8 (4.3) 36.3 (11.8)
P value 0.0036 < 0.0001 0.0009 0.0006
Levels of Hb (g/dL)
<9 g/dL 8.7 (3.6) 8.8 (4.1) 11 (5.5) 29.4 (12.9)
9–10 g/dL 10.8 (4.7) 10.8 (3.6) 9.3 (3.9) 31.2 (11.1)
10–11 g/dL 10.9 (4.8) 11.0 (3.6) 10.5 (4.4) 32.8 (11.7)
11–12 g/dL 11.5 (4.8) 11.7 (4) 11.1 (4.7) 34.4 (12.4)
>12 g/dL 12.1 (4.6) 12.4 (3.7) 12.1 (4.2) 36.9 (11.5)
P value 0.0010 <0.0001 0.0015 0.0006
Pearson’s correlation coefficient 0.14 0.20 0.18 0.18
VAS visual analogue scale, SD standard deviation, Hb haemoglobin
Table 4 Variables associated with the overall scores of the Perform
Questionnaire (linear regression model) (N=298)
Variable Coefficient β P
Need for caregiver −4.37 0.0003
Educational level 1.33 0.0303
Cancer location 0.26 0.0278
Fatigue intensity level −0.30 <0.0001
Karnofsky 0.13 0.0113
Patient in treatment or in follow-up 5.04 0.0146
In palliative treatment or not 2.71 0.0293
Time from diagnosis 0.35 0.0054
Model significance, P<0.0001; R
2 =0.3065
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concentrated on assessing the behaviour of the PQ’s scores
in certain patient profiles that, a priori, were appreciably
different with respect to the perception of fatigue. In this
sense, and consistent with the expected results, the PQ
scores, i.e. the perception of fatigue, were worse in patients
with greater fatigue intensity, patients who needed and had
a caregiver involved in their daily lives, and patients
suffering from anaemia or with lower Hb levels. These
studies are coherent with the results reflecting a low or
Table 5 Sensitivity to change and clinical significance of the improvement of the Perform Questionnaire Score
Physical limitations Activities of
daily living
Beliefs and attitudes Global score
Sensitivity to improvement
a (N=208)
Mean score (SD), visit 1 11.7 (4.6) 11.8 (3.7) 11.5 (4.4) 35.3 (11.7)
95% CI 11.1–12.4 11.3–12.3 10.8–12.1 33.5–37.1
Mean score (SD), visit 2 13.9 (4.1) 13.9 (3.4) 13.6 (4.1) 41.4 (10.7)
95% CI 13.3–14.5 13.4–14.3 13.0–14.2 39.8–43.0
Effect size 0.5 0.6 0.5 0.5
SRM 0.49 0.50 0.55 0.57
Sensitivity to deterioration
b (N=84)
Mean score (SD), visit 1 11.6 (4.6) 12.2 (3.9) 11.4 (4.4) 35.6 (11.7)
95% CI 10.6–12.6 11.3–13.0 10.4–12.5 32.7–38.4
Mean score (SD), visit 2 8 (3.7) 8.6 (3.3) 8.1 (3.6) 25.1 (10)
95% CI 7.1–8.8 7.9–9.4 7.3–9.0 22.7–27.6
Effect size −0.9 −1 −0.8 −1
SRM −0.73 −0.83 −0.73 −0.76
Clinical significance (N=288)
Mean change (SD) among stable patients
c 0.22 (4.97) 0.40 (4.61) 0.10 (4.45) 0.03 (12.69)
Mean change (SD) among improved patients
d 1.43 (4.74) 1.15 (4.23) 1.30 (4.31) 3.72 (10.22)
Minimally important difference (MID)
e 1.21 0.75 1.2 3.69
Overall score ranges from 12 to 60, with low scores indicating worse patient perception of cancer-related fatigue. Dimension scores range from 4
to 20, with low scores indicating worse patient perception of cancer-related fatigue
SD standard deviation, SRM standardised response mean, CI confidence interval
aAmong those patients who reported an improvement in the “health status transition item”
bAmong those patients who reported a deterioration in the “health status transition item”
cPatients who experienced a change in Hb<1 g/dL to a lower limit of −1 g/dL
dPatients who experienced an increase in Hb≥1 g/dL
eThe difference between the mean change of stable patients and the mean change of those who improved
Fig. 1 Pearson Correlation be-
tween the Perform Question-
naire and the FACT-F, NHP-22
and Karnofsky scores (N=437)
Support Care Cancer (2011) 19:657–666 663moderate association with the scores of others fatigue scales
(mainly through the use of the FACT-F or FACT-An
questionnaires; similar data have not been found in other
questionnaires) and Hb levels [18, 34–37]. However, no
previous studies used a standardised scale for the assess-
ment of fatigue associated with the need for a caregiver
involved in the daily lives of cancer patients, which is
further proof of the validity of the PQ. In addition, the
multivariate analysis showed that two of the above-
mentioned variables (need for a caregiver and fatigue
intensity) were independent variables particularly associat-
ed with the overall PQ scores.
The behaviour analysis of the PQ scores was also
focused on the assessment of convergent and divergent
validity with respect to specific health questionnaires for
fatigue, such as the FACT-F (convergent validity), and
with respect to non-specific questionnaires for fatigue,
such as the NHP and Karnofsky index (divergent
validity). The relationship between the Perform and
FACT-F questionnaires was, as expected, high to very
high, as these are tools whose content is well associated.
However, the relationship between the PQ and the NHP
was more moderate, and the correlation between the PQ
and the Karnofsky index was low. This pattern of
correlations, which was consistent with what was
expected (the greater the similarity in assessed concepts,
the greater the relationship and vice versa) was repro-
duced for both the overall scores of the questionnaire and
for the dimension scores, and was consistent with
associations between performance status and diverse
fatigue questionnaires reported previously [18, 35, 38–
40].
Sensitivity to change in the Perform scores was assessed.
This property was analysed using two subgroups of
patients: those who considered that their health status with
respect to fatigue had “improved” since the previous visit
and those who considered that it had “worsened”. In both
groups, the questionnaire scores underwent an expectable,
coherent, and consistent change for better or worse,
respectively. The change was from slight to moderate in
patients who showed a certain improvement according to
the interpretation of Cohen’sE S[ 26]. In patients who
reported a worsening in their health status, the ES was
between moderate and great, which indicates that the
change had been greater (worse) among those who had
reported worsening than among those who had reported an
improvement. Sensitivity to change, a metric property that
indicates the extent of the ability of the questionnaire to
detect change (from better to worse) within the health
concept assessed by the patients, is rarely tested when
validating these kinds of questionnaires [35, 41], although
knowledge of the sensitivity of a measure for fatigue in
cancer would allow suitable follow-up of the health status
of oncology patients. In this case, we demonstrated the
sensitivity of the PQ regarding improvement and worsening
of fatigue, which could be of great use in clinical practice
and for research purposes.
Finally, and following the recommendations of the
most recent guidelines [29], it was desirable to estimate
the minimum change (improvement) in the overall score of
the PQ required to identify a clinical relevant improve-
ment. Using an adaptation of the method used previously
[27], we estimated in 3.5 points the aforementioned
minimum change in the overall PQ score, and this value
would represent an improvement of 1 g/dL in patients’ Hb
levels.
In conclusion, the PQ is a questionnaire designed to
assess the attitudes and beliefs about fatigue in cancer and
its treatment in clinical practice that is feasible, reliable,
valid, and sensitive to improvement or deterioration. Its
characteristics, content, and demonstrated psychometric
properties are likely to render it highly applicable for use
Fig. 2 Effect sizes obtained for
the Perform Questionnaire
among patients who reported on
improvement or deterioration,
respectively, in the "health status
transition item"
664 Support Care Cancer (2011) 19:657–666in clinical practice in different Spanish-speaking target
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